文献速递药物相互作用

美他米唑对健康志愿者CYP3A活性的时间过程影响

Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers.
PubMed 文献 · Br J Clin Pharmacol · 2023-04-01

该研究在健康志愿者中使用咪达唑仑微剂量评估美他米唑对CYP3A活性的诱导时间过程。结果显示,美他米唑治疗开始3天后CYP3A活性即显著改变,稳态时咪达唑仑AUC2-4几何均值比降至0.18,eClmet升高5.43倍;停药后第5天仍显著未恢复。结论提示美他米唑是强CYP3A诱导剂,应避免与窄治疗指数且主要经CYP3A清除的药物合用。

要点

  • 美他米唑开始3天后即显著诱导CYP3A活性。
  • 稳态时咪达唑仑AUC2-4降至0.18,eClmet升高5.43倍。
  • 停药后第5天CYP3A活性仍未完全恢复。

核心结论

  • 美他米唑是CYP3A的强诱导剂,开始给药后数天即起效,停药后恢复缓慢。
  • 应避免美他米唑与窄治疗指数且主要经CYP3A清除的药物合用。
  • 若必须合用,应在美他米唑开始后第一周内及停药后密切监测并调整合用药剂量。

研究设计与样本

  • 健康志愿者自身对照研究,使用口服咪达唑仑微剂量30 μg作为CYP3A指数底物。
  • 在美他米唑3×1000 mg/日口服8天之前、稳态时及停药后评估咪达唑仑药代动力学。

主要发现

  • 美他米唑治疗开始3天后即检测到药代动力学参数显著变化。
  • 酶诱导稳态时,咪达唑仑AUC2-4几何均值比降至0.18(90%CI 0.14-0.24)。
  • 稳态时eClmet升高5.43倍(90%CI 4.15-7.10)。
  • 停药后第5天AUC2-4仍降至0.50(90%CI 0.41-0.63),eClmet仍升高1.99倍(90%CI 1.60-2.47,P<0.05)。

临床怎么用

  • 使用美他米唑前应审查合并用药中是否含窄治疗指数且主要经CYP3A清除的药物。
  • 合用时应从美他米唑开始第一周起及停药后密切监测合用药疗效或毒性并调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In patients of all ages, metamizole is a frequently used analgesic. Recently, metamizole has been identified as an inducer of, among others, cytochrome P450 (CYP) 3A activity, but the time course of this interaction has not been evaluated. METHODS: Using repeated oral microdoses (30 μg) of the CYP3A index substrate midazolam, we assessed changes in midazolam pharmacokinetics (area under the concentration-time curve from 2-4 h: AUC2-4 and estimated partial metabolic clearance: eClmet ) before, at steady-state, and after discontinuation of 3 × 1000 mg metamizole/day orally for 8 days. RESULTS: Significant changes in pharmacokinetic parameters were detected already 3 days after start of metamizole treatment. At the steady-state of enzyme induction, the geometric mean ratio of midazolam AUC2-4 was substantially reduced to 0.18 (90% confidence interval: 0.14-0.24) with a corresponding 5.43-fold (4.15-7.10) increase of eClmet . After discontinuation of metamizole, the changes slowly recovered, but were still significant at the end of the observation period on the fifth day after discontinuation of metamizole therapy (AUC2-4 reduced to 0.50 [0.41-0.63] and eClmet 1.99-fold increased [1.60-2.47, P < 0.05]). CONCLUSION: Metamizole acts as a strong inducer of CYP3A already few days after start of metamizole administration and, thus, should be avoided in patients using drugs with narrow therapeutic index and major clearance via CYP3A. If their administration is essential, close monitoring and dose adjustment of comedication should be performed as early as the first week after the initiation and after discontinuation of metamizole therapy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Breithaupt MH, Krohmer E, Taylor L, et al. Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers. Br J Clin Pharmacol. 2023. PMID: 36946257. doi:10.1111/bcp.15720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。